Iongen Therapeutics Co., Ltd. ("Iongen Therapeutics"), abiotechnology company developing best-in-class non-opioid pain medicines,announced the successful completion of its Pre-A financing round, raising over100 million RMB. The round was led by Qiming Venture Partners. The investment will support the company'spreclinical and early clinical development of its management portfolio, with afocus on accelerating the development of novel Nav1.8 sodium channel-targetingsmall-molecule drug.
"Our team has long been dedicated to fundamental research on ionchannels," said Professor Lei Xiaoguang, Co-Founder of IongenTherapeutics. "By positioning Iongen Therapeutics as a specialized ionchannel drug development platform, we aim to accelerate the development ofnovel pain therapies and benefit millions of patients worldwide. We aregrateful for the unwavering confidence investors have in our assets andplatform, and confident that this round will accelerate a smooth and successfulexecution of our pipeline."
Dr. Chen Kan, Partner and Co-Lead of Healthcare at Qiming Venture Partners,added, "We are impressed by Iongen Therapeutics' innovative approach andscientific expertise in ion channel-targeted drug development. We believe thecompany's strong R&D capabilities will lead to breakthrough therapies, bringinghope and relief to the growing global population of patients suffering from pain."
The round was led by Qiming Venture Partners and joined by Insight Capital and Tsinghua Holdings Ginkgo.
（转自：启明创投）
“掌”握科技鲜闻 （微信搜索techsina或扫描左侧二维码关注）
